{"id":"subcutaneous-immunotherapy","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Local reactions"},{"rate":"1-5%","effect":"Systemic reactions"},{"rate":"rare (<1%)","effect":"Anaphylaxis"}]},"_chembl":{"chemblId":"CHEMBL2108717","moleculeType":"Cell"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This treatment works by gradually exposing the body to small, controlled amounts of the allergen, allowing the immune system to adjust and become less reactive over time. The goal is to desensitize the individual and prevent severe allergic reactions.","oneSentence":"Subcutaneous immunotherapy involves administering allergens or allergen extracts under the skin to build tolerance and reduce allergic reactions.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:33.991Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allergic rhinitis"},{"name":"Allergic asthma"}]},"trialDetails":[{"nctId":"NCT05642195","phase":"PHASE1, PHASE2","title":"Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT07388563","phase":"PHASE1","title":"Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Lymphoma, T Cell, Peripheral, T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma","enrollment":20},{"nctId":"NCT07492875","phase":"PHASE3","title":"Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2026-04-15","conditions":"Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS), Sepsis","enrollment":10},{"nctId":"NCT03568058","phase":"PHASE1","title":"Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers","status":"COMPLETED","sponsor":"Aaron Miller","startDate":"2018-07-26","conditions":"Advanced Cancer","enrollment":25},{"nctId":"NCT06325709","phase":"PHASE1, PHASE2","title":"Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-04-17","conditions":"Chronic Granulomatous Disease (CGD), X-Linked Chronic Granulomatous Disease","enrollment":10},{"nctId":"NCT06450041","phase":"PHASE2","title":"NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial","status":"RECRUITING","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2024-12-16","conditions":"Neuroblastoma","enrollment":62},{"nctId":"NCT07419230","phase":"NA","title":"Evaluation of a Digital Tool to Improve Aeroallergen Immunotherapy Adherence. NavigAITme Project","status":"RECRUITING","sponsor":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","startDate":"2026-03-11","conditions":"Allergic Rhinitis","enrollment":880},{"nctId":"NCT06738160","phase":"PHASE2","title":"The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-02-15","conditions":"NSCLC, Stereotactic Body Radiation Therapy (SBRT), Immunotherapy","enrollment":27},{"nctId":"NCT07412990","phase":"","title":"GRASS (Grass MATA MPL Real-world Assessment Study)","status":"RECRUITING","sponsor":"Allergy Therapeutics","startDate":"2026-03-11","conditions":"Grass Pollen Allergy","enrollment":1000},{"nctId":"NCT07477366","phase":"PHASE2","title":"Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2026-04","conditions":"Relapsed B-Cell Non-Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT07161414","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-25","conditions":"Advanced Solid Tumors","enrollment":40},{"nctId":"NCT06960382","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Asthma","status":"RECRUITING","sponsor":"University of Zurich","startDate":"2025-08-20","conditions":"Allergic Rhinitis, Allergic Asthma","enrollment":36},{"nctId":"NCT07125872","phase":"PHASE2","title":"Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-11-11","conditions":"Relapsed B-Cell Non Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT07447869","phase":"EARLY_PHASE1","title":"LYmph Node eXamination in Cat Allergen Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-03-19","conditions":"Allergy","enrollment":16},{"nctId":"NCT04347616","phase":"PHASE1, PHASE2","title":"Natural Killer-cell Therapy for Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2020-12-03","conditions":"Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, Relapsed, Adult","enrollment":9},{"nctId":"NCT00820820","phase":"NA","title":"IDA (Immunothérapie de la Dermatite Atopique) Adult - Immunotherapy in Atopic Dermatitis","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2009-01-09","conditions":"Atopic Dermatitis","enrollment":20},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT07468630","phase":"PHASE2","title":"Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2026-04-10","conditions":"Colon Adenocarcinoma","enrollment":106},{"nctId":"NCT05361798","phase":"PHASE2","title":"T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-06-12","conditions":"Cancer Of Prostate","enrollment":65},{"nctId":"NCT06149481","phase":"PHASE1, PHASE2","title":"Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-03-26","conditions":"Metastatic Colorectal Cancer","enrollment":60},{"nctId":"NCT07452380","phase":"","title":"The Efficacy of Specific Immunotherapy Guided by Component-Resolved Diagnosis for Dust Mite Allergens in Chinese Pediatric Patients With Rhinitis and/or Asthma","status":"RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2025-11-01","conditions":"Allergic Rhinitis Due to House Dust Mite","enrollment":1000},{"nctId":"NCT06933251","phase":"PHASE2","title":"PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2025-01-20","conditions":"Locally Advanced Rectal Cancer (LARC)","enrollment":30},{"nctId":"NCT05707910","phase":"PHASE1","title":"Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"West China Hospital","startDate":"2023-02-08","conditions":"Malignant Tumor","enrollment":6},{"nctId":"NCT04221542","phase":"PHASE1","title":"Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Amgen","startDate":"2020-03-04","conditions":"Prostate Cancer","enrollment":479},{"nctId":"NCT06253494","phase":"PHASE1, PHASE2","title":"Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-05-14","conditions":"Endometrial Cancer, Cancer of Endometrium, Carcinoma of Endometrium","enrollment":60},{"nctId":"NCT06239220","phase":"PHASE2","title":"PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC","status":"RECRUITING","sponsor":"Glenn J. Hanna","startDate":"2024-02-16","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer","enrollment":25},{"nctId":"NCT07430202","phase":"PHASE1","title":"A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)","status":"NOT_YET_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-05","conditions":"Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))","enrollment":27},{"nctId":"NCT05428969","phase":"PHASE1, PHASE2","title":"A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Faron Pharmaceuticals Ltd","startDate":"2022-06-02","conditions":"Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes","enrollment":181},{"nctId":"NCT06622434","phase":"PHASE1, PHASE2","title":"New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-11-08","conditions":"Newly Diagnosed Glioblastoma","enrollment":35},{"nctId":"NCT06027086","phase":"PHASE1, PHASE2","title":"DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2024-02-12","conditions":"Fibrolamellar Hepatocellular Carcinoma","enrollment":27},{"nctId":"NCT05726383","phase":"PHASE2","title":"Iscador® P (Mistletoe) Immunotherapy for Recurrent Osteogenic Sarcoma","status":"RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2024-05-14","conditions":"Osteogenic Sarcoma Recurrent","enrollment":32},{"nctId":"NCT07388758","phase":"PHASE2","title":"Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":37},{"nctId":"NCT05733611","phase":"PHASE2","title":"RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC","status":"TERMINATED","sponsor":"Replimune Inc.","startDate":"2023-06-29","conditions":"Refractory Metastatic Colorectal Cancer, pMMR, MSS","enrollment":5},{"nctId":"NCT07374029","phase":"PHASE1","title":"Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML","status":"NOT_YET_RECRUITING","sponsor":"David Avigan","startDate":"2026-07","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse","enrollment":30},{"nctId":"NCT04183166","phase":"PHASE1, PHASE2","title":"A Clinical Trial Evaluating TG4050 in Head and Neck Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Transgene","startDate":"2019-12-12","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":80},{"nctId":"NCT03228667","phase":"PHASE2","title":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-12-11","conditions":"Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma","enrollment":40},{"nctId":"NCT05852717","phase":"PHASE2","title":"Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Dipenkumar Modi","startDate":"2023-10-31","conditions":"Large Cell Lymphoma, Diffuse, Relapsed Cancer, Refractory Cancer","enrollment":32},{"nctId":"NCT07317960","phase":"PHASE1","title":"Phase I Study of PollenVax in Patients With Mugwort Pollen-Induced Allergic Rhinitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kazakh National Agrarian University","startDate":"2025-11-22","conditions":"Allergic Rhinitis Due to Artemisia Pollen","enrollment":30},{"nctId":"NCT07307053","phase":"PHASE1, PHASE2","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":600},{"nctId":"NCT04847466","phase":"PHASE2","title":"Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-12-14","conditions":"Gastroesophageal Junction (GEJ) Cancers, Advanced HNSCC","enrollment":18},{"nctId":"NCT05783609","phase":"PHASE2","title":"Epcoritamab and Rituximab for First-line Follicular Lymphoma","status":"RECRUITING","sponsor":"Reid Merryman, MD","startDate":"2023-06-21","conditions":"Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult","enrollment":100},{"nctId":"NCT06411691","phase":"PHASE1","title":"KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-06-24","conditions":"Colorectal Cancer, Pancreatic Cancer","enrollment":54},{"nctId":"NCT03388632","phase":"PHASE1","title":"Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-02-05","conditions":"Metastatic Solid Tumors, Treatment-Refractory Cancers","enrollment":31},{"nctId":"NCT03281369","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-10-13","conditions":"Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma","enrollment":214},{"nctId":"NCT05455112","phase":"PHASE2","title":"Safety and Efficacy of RUTI® With the Standard of Treatment for Tuberculosis","status":"COMPLETED","sponsor":"Archivel Farma S.L.","startDate":"2022-10-29","conditions":"Tuberculosis, Pulmonary","enrollment":41},{"nctId":"NCT06876506","phase":"","title":"Identification of B Regulatory Cells by Flow Cytometry","status":"NOT_YET_RECRUITING","sponsor":"Hull University Teaching Hospitals NHS Trust","startDate":"2026-02-01","conditions":"Pollen Allergy, Venom Allergy","enrollment":80},{"nctId":"NCT07266493","phase":"PHASE2","title":"Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2023-12-01","conditions":"Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy","enrollment":26},{"nctId":"NCT03117751","phase":"PHASE2, PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma","enrollment":790},{"nctId":"NCT06782932","phase":"PHASE1, PHASE2","title":"Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-05-27","conditions":"Pancreatic Cancer","enrollment":38},{"nctId":"NCT02950259","phase":"PHASE1","title":"Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)","status":"COMPLETED","sponsor":"Providence Health & Services","startDate":"2017-02-09","conditions":"Breast Neoplasm, Breast Neoplasm, Male, Triple Negative Breast Cancer","enrollment":16},{"nctId":"NCT07249372","phase":"PHASE2","title":"DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-12-01","conditions":"Non Small Cell Lung Cancer","enrollment":37},{"nctId":"NCT07247097","phase":"PHASE2","title":"ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-04-15","conditions":"Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible","enrollment":160},{"nctId":"NCT03193190","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-07-05","conditions":"Pancreatic Adenocarcinoma","enrollment":341},{"nctId":"NCT03498521","phase":"PHASE2","title":"A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-07-10","conditions":"Cancer of Unknown Primary Site","enrollment":529},{"nctId":"NCT03839524","phase":"PHASE1","title":"A Trial Evaluating TG4050 in Ovarian Carcinoma.","status":"COMPLETED","sponsor":"Transgene","startDate":"2019-12-09","conditions":"Ovarian Carcinoma, Fallopian Tube Cancer, Peritoneal Carcinoma","enrollment":64},{"nctId":"NCT07015996","phase":"PHASE2","title":"Efficacy of Tezepelumab in Peanut Oral Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-02-18","conditions":"Peanut Allergy","enrollment":62},{"nctId":"NCT00669734","phase":"PHASE1","title":"Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-02-01","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma","enrollment":18},{"nctId":"NCT06455605","phase":"PHASE1","title":"D2C7-IT + 2141-V11 Combination Post-resection in rGBM","status":"RECRUITING","sponsor":"Darell Bigner","startDate":"2025-03-17","conditions":"Recurrent Glioblastoma IDH Wildtype","enrollment":46},{"nctId":"NCT02668770","phase":"PHASE1","title":"Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-05-11","conditions":"Advanced Cancers, Melanoma","enrollment":28},{"nctId":"NCT06544655","phase":"PHASE1","title":"A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2024-10-10","conditions":"Advanced Solid Tumors","enrollment":213},{"nctId":"NCT07217665","phase":"PHASE2","title":"The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1","status":"NOT_YET_RECRUITING","sponsor":"Adam Boxer","startDate":"2025-12-01","conditions":"PSP - Progressive Supranuclear Palsy","enrollment":146},{"nctId":"NCT06956547","phase":"","title":"Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation Therapy","status":"AVAILABLE","sponsor":"ImmunityBio, Inc.","startDate":"","conditions":"Lymphopenia","enrollment":""},{"nctId":"NCT05734560","phase":"PHASE1, PHASE2","title":"D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients","status":"RECRUITING","sponsor":"Darell Bigner","startDate":"2023-09-06","conditions":"Newly Diagnosed MGMT Unmethylated Glioblastoma","enrollment":50},{"nctId":"NCT04260126","phase":"PHASE2","title":"Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC","status":"COMPLETED","sponsor":"PDS Biotechnology Corp.","startDate":"2021-03-29","conditions":"Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma","enrollment":95},{"nctId":"NCT07090174","phase":"PHASE2","title":"Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIV","status":"NOT_YET_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2025-10-20","conditions":"HPV Associated Cancers, HIV (Human Immunodeficiency Virus), Anal Cancer","enrollment":27},{"nctId":"NCT07199413","phase":"PHASE1","title":"Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2026-03-01","conditions":"Brain Metastases, Leptomeningeal Metastasis","enrollment":20},{"nctId":"NCT03493945","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-05-01","conditions":"Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Neoplasm","enrollment":59},{"nctId":"NCT07185893","phase":"NA","title":"A Multicenter, Open-label, Randomized Controlled Trial Evaluating the Efficacy and Safety of Romiplostim N01 in the Treatment of Thrombocytopenia Associated With Concurrent/Sequential Chemoradiotherapy and Chemotherapy Combined With/Without Immunotherapy in Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Jun wang","startDate":"2025-09","conditions":"Solid Tumor Malignancies, Cancer, CTIT-Chemotherapy Induced Thrombocytopenia, Thrombocytopenia","enrollment":106},{"nctId":"NCT06285097","phase":"PHASE1","title":"A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Pfizer","startDate":"2024-02-08","conditions":"Neoplasms, Non-small-cell Lung Cancer, Melanoma","enrollment":9},{"nctId":"NCT03881696","phase":"PHASE3","title":"Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-07-22","conditions":"Peanut Allergy, Multi-food Allergy","enrollment":471},{"nctId":"NCT07163104","phase":"NA","title":"The Effects of Nonpharmacological Methods Used in Subcutaneous Application on Pain, Anxiety, and Fear Levels in Children","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zubeyde Ezgi Ercelik","startDate":"2025-02-10","conditions":"Pediatric Oncology","enrollment":72},{"nctId":"NCT04853017","phase":"PHASE1","title":"A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors","status":"COMPLETED","sponsor":"Elicio Therapeutics","startDate":"2021-10-04","conditions":"Minimal Residual Disease, KRAS G12D, KRAS G12R","enrollment":25},{"nctId":"NCT06448585","phase":"PHASE4","title":"Dietary Supplement (Beta-Glucans) in Allergic Patients Undergoing Subcutaneous Immunotherapy.","status":"COMPLETED","sponsor":"Gala Servicios Clinicos S.L.","startDate":"2024-05-29","conditions":"Rhinitis, Allergic Rhinoconjunctivitis, Rhinoconjunctivitis","enrollment":60},{"nctId":"NCT05155254","phase":"PHASE3","title":"IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)","status":"ACTIVE_NOT_RECRUITING","sponsor":"IO Biotech","startDate":"2022-05-17","conditions":"Metastatic Melanoma, Unresectable Melanoma","enrollment":407},{"nctId":"NCT03677154","phase":"PHASE1, PHASE2","title":"Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-05-23","conditions":"Diffuse Large B-cell Lymphoma","enrollment":188},{"nctId":"NCT06605963","phase":"PHASE2","title":"PPV-06 Vaccine in Inflammatory Knee Osteoarthritis","status":"NOT_YET_RECRUITING","sponsor":"Peptinov SAS","startDate":"2025-12","conditions":"Osteoarthritis, Knee","enrollment":204},{"nctId":"NCT06762769","phase":"PHASE2","title":"Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma","status":"RECRUITING","sponsor":"University College, London","startDate":"2025-06-02","conditions":"Smouldering Myeloma","enrollment":63},{"nctId":"NCT01192555","phase":"PHASE1, PHASE2","title":"Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2010-09","conditions":"Neuroblastoma","enrollment":11},{"nctId":"NCT03806309","phase":"PHASE2","title":"OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2021-04-10","conditions":"Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer, Metastatic Cancer","enrollment":106},{"nctId":"NCT02264236","phase":"PHASE1, PHASE2","title":"Vaccination of Advanced-Stage Lung Cancer Patients","status":"WITHDRAWN","sponsor":"University of Arkansas","startDate":"2015-10","conditions":"Lung Neoplasms","enrollment":""},{"nctId":"NCT04247282","phase":"PHASE1, PHASE2","title":"Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2020-06-09","conditions":"Head and Neck Cancer, Head and Neck Neoplasms","enrollment":21},{"nctId":"NCT04502966","phase":"PHASE2","title":"Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-11-09","conditions":"Allergic Rhinoconjunctivitis, Grass Pollen Allergy","enrollment":108},{"nctId":"NCT02015104","phase":"PHASE2","title":"Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-12-18","conditions":"Bladder Cancer","enrollment":32},{"nctId":"NCT05153070","phase":"PHASE2","title":"Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-09-21","conditions":"Type 1 Diabetes","enrollment":24},{"nctId":"NCT04543071","phase":"PHASE2","title":"Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Gulam Manji","startDate":"2020-11-09","conditions":"Pancreatic Cancer, Adenocarcinoma of the Pancreas, Adenocarcinoma","enrollment":10},{"nctId":"NCT03315871","phase":"PHASE2","title":"Combination Immunotherapy in Biochemically Recurrent Prostate Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-03-20","conditions":"Prostate Cancer","enrollment":40},{"nctId":"NCT04830124","phase":"PHASE2","title":"Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6","status":"TERMINATED","sponsor":"Mural Oncology, Inc","startDate":"2021-09-27","conditions":"Cutaneous Melanoma, Mucosal Melanoma","enrollment":173},{"nctId":"NCT05704985","phase":"PHASE1","title":"Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"DEKA Biosciences","startDate":"2023-04-03","conditions":"Cancer, Solid Tumor, Colorectal Cancer","enrollment":39},{"nctId":"NCT05960266","phase":"EARLY_PHASE1","title":"Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2023-11-23","conditions":"Hypersensitivity, Hay Fever, Rhinitis, Allergic, Seasonal","enrollment":28},{"nctId":"NCT03958565","phase":"","title":"Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2020-04-28","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":100},{"nctId":"NCT05141721","phase":"PHASE2, PHASE3","title":"A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seattle Project Corporation","startDate":"2022-02-12","conditions":"Colorectal Neoplasms","enrollment":700},{"nctId":"NCT04898283","phase":"PHASE3","title":"Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.","status":"RECRUITING","sponsor":"Inmunotek S.L.","startDate":"2021-05-31","conditions":"Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic","enrollment":180},{"nctId":"NCT04435990","phase":"PHASE3","title":"Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites","status":"RECRUITING","sponsor":"Inmunotek S.L.","startDate":"2020-10-06","conditions":"Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic","enrollment":150},{"nctId":"NCT04891237","phase":"PHASE3","title":"Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen","status":"RECRUITING","sponsor":"Inmunotek S.L.","startDate":"2021-06-14","conditions":"Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic","enrollment":180},{"nctId":"NCT04261439","phase":"PHASE1","title":"A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-02-27","conditions":"In Escalation: All Patients With Solid Tumors and Lymphoma, In Expansion: Melanoma, Non-small Cell Lung Cancer","enrollment":60},{"nctId":"NCT06765902","phase":"PHASE2","title":"Immunotherapy Before and After Surgery","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-05-15","conditions":"High-risk Prostate Cancer","enrollment":20},{"nctId":"NCT04491955","phase":"PHASE2","title":"Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-22","conditions":"Small Bowel Cancers, Colorectal Cancers","enrollment":32},{"nctId":"NCT03954067","phase":"PHASE1","title":"A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2019-09-03","conditions":"Metastatic Cancer, Solid Tumors, Advanced Cancer","enrollment":72},{"nctId":"NCT04287868","phase":"PHASE1, PHASE2","title":"Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-06-09","conditions":"Cervical Cancer, HPV Cancers, Anal Cancer","enrollment":51},{"nctId":"NCT06920771","phase":"PHASE3","title":"A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"HAL Allergy","startDate":"2024-09-09","conditions":"House Dust Mite Allergy, House Dust Mite Rhinitis","enrollment":552}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1288,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ALK-depot SQ mites","AVANZ"],"phase":"phase_3","status":"active","brandName":"subcutaneous immunotherapy","genericName":"subcutaneous immunotherapy","companyName":"ALK-Abelló A/S","companyId":"alk-abell-a-s","modality":"Biologic","firstApprovalDate":"","aiSummary":"Subcutaneous immunotherapy involves administering allergens or allergen extracts under the skin to build tolerance and reduce allergic reactions. Used for Allergic rhinitis, Allergic asthma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}